- From: 9 November 2026
- What: NPPA capped trade margins on 137 anti-cancer drugs
- Estimated saving: about Rs 3,502.31 crore a year
Greater Kashmir reports that 76 companies reported revised MRPs for 1,225 formulations across 121 drugs, that 600 brands were cut by more than 50 per cent, and that the largest cut was 96.45 per cent. It also says the NPPA described the aim as "improving the affordability and accessibility of essential anti-cancer medicines."
Examples from the report
- Bevacizumab (Bryxta): Rs 25,995 to Rs 3,318
- Abiraterone (Abirone): Rs 41,250 to Rs 3,218.23
- Palbopro: Rs 40,421.33 to Rs 2,720
Why it matters in Jammu
Jammu is the region's referral hub, with AIIMS Jammu and GMC Jammu drawing patients from across the division, and a family member's treatment is often a young adult's responsibility to manage.
Check before you pay
- Look up the ceiling price on the Pharma Sahi Daam app or the NPPA website.
- Retailers and hospitals must display the revised price lists; ask to see them.
- Report overcharging to the NPPA helpline, 1800-11-1255. State Drug Controllers monitor compliance.
Prices on old stock may differ for a short time; ask the chemist to show the revised MRP before paying.

%2Fgreater-kashmir%2Fmedia%2Fmedia_files%2F2026%2F11%2F12%2Fjammu-award-2026-11-12-07-29-09.png&w=3840&q=75)



